CoChat

Combination therapy: the future of management for idiopathic pulmonary fibrosis?

The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.

Abstract

Findings from recently published placebo-controlled trials in idiopathic pulmonary fibrosis have established that pirfenidone and nintedanib prevent about 50% of the decline in forced vital capacity typically seen in this disease; future trials are therefore unlikely to use placebo as a control group for ethical reasons. Future clinical assessment will probably include add-on trials in which a new drug is combined with an intervention with established efficacy; this development is in turn likely to herald the use of combination regimens in clinical practice. Personalised medicine (the selection of monotherapies on the basis of individualised biomarker signal) is an intrinsically attractive alternative approach, but is unlikely to be useful in routine management of idiopathic pulmonary fibrosis in the medium-term future because of the complex nature of the disease's pathogenesis. In this Personal View, we review the pleiotropic nature of disease pathogenesis in idiopathic pulmonary disease, the use of combination regimens in other selected chronic lung diseases, and the conceptual basis for combination therapies in interstitial lung disorders other than idiopathic pulmonary fibrosis. On the basis of these considerations, and the emergence of data from add-on trials, we believe that the future of management for idiopathic pulmonary fibrosis lies in the development of combination regimens.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(14)70232-2

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 65 references

Cited by

See all 150

Metadata

Authors
Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., Vancheri, C., & Wells, A. U.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • University of Crete (GR)
  • Inserm (FR)
  • Ruhrlandklinik (DE)
  • Lyon 1 Université (FR)
  • University Medical Center Utrecht (NL)
  • Royal Brompton Hospital (GB)
  • Ospedale G.B. Morgagni - L.Pierantoni (IT)
  • University Hospital Southampton NHS Foundation Trust (GB)
  • University of Catania (IT)
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2014-11
Volume
2
Issue
11
Pages
933-942
ISSN
2213-2600 (ISSN-L)
OpenAlex
W2011826235
Cited by
150
References
66
Citations by year
2026: 3 · 2025: 10 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 8 · 2020: 9 · 2019: 21 · 2018: 12 · 2017: 23 · 2016: 23 · 2015: 22
FWCI
3.88
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Lirias (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, combination therapy, pirfenidone, nintedanib, adjunctive therapy, interstitial lung disease, chronic lung disease, personalized medicine, biomarkers, pathogenesis, forced vital capacity decline
MeSH terms
Asthma, Drug Therapy, Combination, Humans, Hypertension, Pulmonary, Lung Neoplasms, Lung Diseases, Interstitial, Pulmonary Disease, Chronic Obstructive, Idiopathic Pulmonary Fibrosis, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination therapy: the future of management for idiopathic pulmonary fibrosis? https://app.cochat.ai/papers/10.1016/s2213-2600(14)70232-2
The paper
Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., Vancheri, C., & Wells, A. U. (2014). Combination therapy: the future of management for idiopathic pulmonary fibrosis? The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(14)70232-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.